Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of relapsed ovarian cancer: a review
Gonzalo Giornelli
SpringerPlus (2016) Vol. 5, Iss. 1
Open Access | Times Cited: 119

Showing 26-50 of 119 citing articles:

The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients
Emma Åkerlund, Greta Gudoitytė, Elisabeth Moussaud-Lamodière, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 10
Roles of miRNAs in regulating ovarian cancer stemness
Zhi Xiong Chong
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 6, pp. 189191-189191
Closed Access | Times Cited: 3
Development of model for identifying homologous recombination deficiency (HRD) status of ovarian cancer with deep learning on whole slide images
Ke Zhang, Yinghe Qiu, Songwei Feng, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Efficacy and Safety of Combination Therapy with PARP Inhibitors and Anti-Angiogenic Agents in Ovarian Cancer: A Systematic Review and Meta-Analysis
István Baradács, Brigitta Teutsch, Ádám Vincze, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 5, pp. 1776-1776
Open Access
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status
Sandro Pignata, Amit M. Oza, Geoff Hall, et al.
British Journal of Cancer (2025)
Open Access
MiR-19a negatively regulated the expression of PTEN and promoted the growth of ovarian cancer cells
Yuhong Wang, Shuzhen Zhao, Lihong Zhu, et al.
Gene (2018) Vol. 670, pp. 166-173
Closed Access | Times Cited: 31
Human mesenchymal stem cells in the tumour microenvironment promote ovarian cancer progression: the role of platelet-activating factor
Tong Gao, Yi Yu, Qing Cong, et al.
BMC Cancer (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 28
Synergistic effect of Chloroquine and Panobinostat in ovarian cancer through induction of DNA damage and inhibition of DNA repair
María Ovejero-Sánchez, Rogelio González‐Sarmiento, Ana B. Herrero
Neoplasia (2021) Vol. 23, Iss. 5, pp. 515-528
Open Access | Times Cited: 23
Stromal DDR2 Promotes Ovarian Cancer Metastasis through Regulation of Metabolism and Secretion of Extracellular Matrix Proteins
Angela M. Schab, Molly M. Greenwade, Elizabeth Stock, et al.
Molecular Cancer Research (2023) Vol. 21, Iss. 11, pp. 1234-1248
Closed Access | Times Cited: 9
Long non-coding RNA GEHT1 promoted the proliferation of ovarian cancer cells via modulating the protein stability of HIF1α
Dan Liu, Hao Li
Bioscience Reports (2019) Vol. 39, Iss. 5
Open Access | Times Cited: 23
Stereotactic body radiation therapy in the treatment of ovarian cancer
Roman O. Kowalchuk, Michael R. Waters, K. Martin Richardson, et al.
Radiation Oncology (2020) Vol. 15, Iss. 1
Open Access | Times Cited: 23
Zinc oxide nanoparticles inhibit malignant progression and chemotherapy resistance of ovarian cancer cells by activating endoplasmic reticulum stress and promoting autophagy
Wenli Gu, Caihong Yang
Experimental and Therapeutic Medicine (2023) Vol. 26, Iss. 5
Open Access | Times Cited: 7
Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer
Chang-Suk Chae, Elí Terán-Cabanillas, Juan R. Cubillos‐Ruiz
Cancer Immunology Immunotherapy (2017) Vol. 66, Iss. 8, pp. 969-977
Closed Access | Times Cited: 24
Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer
Julia Simões Corrêa Galendi, Maria Del Pilar Estevez Diz, Stephanie Stock, et al.
Applied Health Economics and Health Policy (2020) Vol. 19, Iss. 1, pp. 97-109
Open Access | Times Cited: 19
Linking unfolded protein response to ovarian cancer cell fusion
Lucile Yart, Daniel Bastida-Ruiz, Mathilde Allard, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 12
TIM3 Checkpoint Inhibition Fails to Prolong Survival in Ovarian Cancer-Bearing Mice
Yani Berckmans, Ann Vankerckhoven, Aarushi Audhut, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1147-1147
Open Access | Times Cited: 2
Adipocyte derived exosomes promote cell invasion and challenge paclitaxel efficacy in ovarian cancer
Michael Ellis Williams, David Howard, Claire Donnelly, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 2
Prognostic factors and overall survival among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland study
Mari Lahelma, Heini Rauhamaa, Riikka‐Leena Leskelä, et al.
Acta Oncologica (2024) Vol. 63, pp. 763-771
Open Access | Times Cited: 2
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States
Dominic Muston, Robert Hettle, Matthew Monberg, et al.
Gynecologic Oncology (2020) Vol. 159, Iss. 2, pp. 491-497
Open Access | Times Cited: 18
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, et al.
Therapeutic Advances in Medical Oncology (2022) Vol. 14, pp. 175883592211261-175883592211261
Open Access | Times Cited: 11
Distinct Genomic Profiles Are Associated with Treatment Response and Survival in Ovarian Cancer
Chris J. de Witte, Joachim Kutzera, Arne van Hoeck, et al.
Cancers (2022) Vol. 14, Iss. 6, pp. 1511-1511
Open Access | Times Cited: 10
Panobinostat Synergistically Enhances the Cytotoxicity of Microtubule Destabilizing Drugs in Ovarian Cancer Cells
María Ovejero-Sánchez, Gloria Asensio-Juárez, Myriam González, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13019-13019
Open Access | Times Cited: 10
Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective
Ning Li, Qi Liu, Yu Tian, et al.
Journal of Gynecologic Oncology (2022) Vol. 33, Iss. 6
Open Access | Times Cited: 9
Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes
Sue Cheeseman, Bethany Levick, Will Sopwith, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Association of Multiple High-Risk Factors on Observed Outcomes in Real-World Patients With Advanced Ovarian Cancer Treated With First-Line Therapy
Dana M. Chase, Jessica Perhanidis, Divya Gupta, et al.
JCO Clinical Cancer Informatics (2023), Iss. 7
Open Access | Times Cited: 5

Scroll to top